-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals' reference Haze and pain
.
Fortunately, the new treatment model is gradually breaking the predicament, and more and more patients are regaining the hope of cure under the treatment of doctors who hold sharp weapons
.
This article reports a case of gastric cancer with peritoneal metastasis who had a chance of being cured by first-line treatment with nivolumab combined with chemotherapy
.
Wonderful video of Professor Yan Chao August 25, 2021, the regimen of nivolumab combined with fluorouracil and platinum-based chemotherapy was approved by the National Medical Products Administration (NMPA) for the first-line treatment of advanced or metastatic gastric cancer, gastroesophagus Patients with junction cancer or esophageal adenocarcinoma
.
Immunotherapy, represented by PD-1 inhibitors, has been approved for the first-line indication for advanced gastric cancer for the first time in China! The Medical Oncology Channel invited Professor Yan Chao from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine to share the healing process of a patient encountered in the diagnosis and treatment of gastric cancer for many years, as well as the experience and feelings of many years of medical experience
.
A patient with gastric cancer with peritoneal metastasis was treated with chemotherapy combined with nivolumab, and he was cured.
Professor Yan Chao said: “In February 2020, a young female patient came to my outpatient clinic.
The patient’s condition is summarized as follows: Laparoscopy was performed, and the diagnosis was advanced gastric cancer with peritoneal metastasis
.
Peritoneal cancer index (PCI): 20 points with moderate ascites volume, and peritoneal cancer nodules were clearly peritoneal metastases of poorly differentiated adenocarcinoma
.
CPS score: 5 points
.
Normal mismatch repair protein (pMMR), microsatellite stable (MSS)
.
▎Treatment process: The patient was treated with intraperitoneal combined with systemic chemotherapy and PD-1 inhibitor nivolumab.
After three courses of treatment, the patient’s clinical symptoms were significantly improved, ascites began to subside, and the patient’s appetite and mental symptoms were also Significantly improved
.
After another three courses of treatment with this program, the imaging examination was performed again, and the results indicated that the patient's condition had also been greatly relieved
.
The results of laparoscopic exploration showed that the patient's ascites basically disappeared, and the peritoneal metastases disappeared completely
.
Since the patient’s peritoneal metastases were well controlled, after our evaluation, it was decided to perform surgery on the patient.
Partial gastrectomy combined with D2 lymph node dissection was performed.
The number of lymph node dissections reached 50
.
The pathological results suggest that the patient's tumor has reached a significant decline
.
At the same time, the patient basically recovered 10 days after the operation and can be discharged from the hospital
.
Summary: This case is very successful, and it is a great encouragement to our doctors in gastrointestinal surgery
.
Through this patient's treatment experience, we have also obtained very good social benefits, allowing more patients to believe that our treatment plan can provide a better prognosis for patients with advanced gastric cancer and patients with peritoneal metastasis
.
"Nivolumab combination regimen is recommended to rewrite the guidelines and approved as first-line treatment.
In recent years, the treatment of gastric cancer in China has made great progress
.
In addition to traditional radiotherapy and chemotherapy, the emergence of HER2 targets in advanced gastric cancer has made targeted therapy in Occupy a place in stomach cancer
.
However, HER2-negative patients still account for the majority.
Professor Yan Chao pointed out: "In 2021, nivolumab plus chemotherapy was approved by the National Medical Products Administration (NMPA) of China for the first-line treatment of advanced gastric cancer, which has become an important milestone.
.
released this year China Society of clinical Oncology (CSCO) Guide Conference "edition 2021 CSCO gastric cancer treatment guidelines" recommend HER2-negative population first-line use of immunotherapy, 1A type of evidence class I recommendation, immune-line treatment status improved significantly
.
"the program The approval is based on the CheckMate-649 study [1] that has attracted much attention in recent years.
This global multi-center, randomized, open-label study aims to explore a combination therapy based on nivolumab and compare it to standard chemotherapy.
The efficacy of first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
.
At the American Association for Cancer Research (AACR) annual meeting in 2021, the data of the Chinese subgroup in the CheckMate-649 study was announced.
A total of 208 Chinese patients were included in this analysis.
The results suggest that nivolumab combined with chemotherapy has a median OS of 14.
3 months, better than 10.
3 months in the standard chemotherapy group; patients with PD-L1 CPS ≥ 5 and PD-L1 CPS ≥ 1 have observed clinically significant OS benefits, and there is a trend of better benefits
.
Regardless of the entire patient population or the Chinese subgroup, regardless of the patient's PD-L1 expression level, nivolumab combined with chemotherapy has achieved a full range of breakthroughs in efficacy and produced a satisfactory report card
.
Based on the research results of CheckMate-649, immunotherapy has been advanced to the front line, and the recommendations of the "2021 CSCO Gastric Cancer Diagnosis and Treatment Guidelines" have been rewritten
.
Science is constantly advancing, and immunotherapy has achieved impressive results in the field of gastric cancer in recent years.
When everyone feels hopeless, immunotherapy has brought a ray of life
.
The CheckMate-649 research and the patients' personal experience undoubtedly bring confidence and hope to more gastric cancer patients
.
Expert Profile Professor Yan Chao, Deputy Director of Gastrointestinal Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Director of the Ward; Postdoctoral Fellow, Doctor of Medicine, Deputy Chief Physician of the Japanese Autonomous Medical University; Standing Committee Member of the Peritoneal Tumor Professional Committee of the Chinese Anti-Cancer Association; Chinese Medical Doctor Association Member of Upper Gastrointestinal Surgeons Committee of Surgeons Branch; Young Member of Gastric Cancer Professional Committee of Chinese Anti-Cancer Association; Member of Accelerated Rehabilitation Surgery Group of Gastric Cancer Professional Committee of Chinese Anti-Cancer Association; Member of Gastric Cancer Staging Subcommittee of Professional Committee of Chinese Anti-Cancer Association; China Member of the Youth Committee of the Robot Specialist Committee of the Surgeon Branch of the Physicians Association; member of the Difficult Tumor Professional Committee of the Chinese Medical Education Association; member of the Oncologist Branch of the Shanghai Medical Doctor Association; member of the Gastrointestinal Surgery Group of the General Surgery Branch of the Shanghai Medical Association; Member of the Youth Council of the Cancer Society; Member of the Endoscopic Surgery Group of the Shanghai Anti-Cancer Association Minimally Invasive Tumor Therapy Committee; Member of the Medical Education Reform Expert Steering Committee of the Shanghai Jiaotong University School of Medicine; Member of the Correspondence Editor of Chinese Journal of Gastrointestinal Surgery; Young editorial board member of Chinese Journal of Cancer
.
References: [1].
Shen L, Bai Y, Lin X, et al.
Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis[J].
Cancer Research, 2021, 81(13 Supplement): CT184 Approval number: OPDGI-DG-0029-210908-230908*This article is only It is used to provide scientific information to medical professionals, and does not represent the views of this platform.
Interviews with Chinese Gastrointestinal Cancer Medical Experts-Immunotherapy brings longer-term survival benefits for advanced gastric cancer
.
Fortunately, the new treatment model is gradually breaking the predicament, and more and more patients are regaining the hope of cure under the treatment of doctors who hold sharp weapons
.
This article reports a case of gastric cancer with peritoneal metastasis who had a chance of being cured by first-line treatment with nivolumab combined with chemotherapy
.
Wonderful video of Professor Yan Chao August 25, 2021, the regimen of nivolumab combined with fluorouracil and platinum-based chemotherapy was approved by the National Medical Products Administration (NMPA) for the first-line treatment of advanced or metastatic gastric cancer, gastroesophagus Patients with junction cancer or esophageal adenocarcinoma
.
Immunotherapy, represented by PD-1 inhibitors, has been approved for the first-line indication for advanced gastric cancer for the first time in China! The Medical Oncology Channel invited Professor Yan Chao from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine to share the healing process of a patient encountered in the diagnosis and treatment of gastric cancer for many years, as well as the experience and feelings of many years of medical experience
.
A patient with gastric cancer with peritoneal metastasis was treated with chemotherapy combined with nivolumab, and he was cured.
Professor Yan Chao said: “In February 2020, a young female patient came to my outpatient clinic.
The patient’s condition is summarized as follows: Laparoscopy was performed, and the diagnosis was advanced gastric cancer with peritoneal metastasis
.
Peritoneal cancer index (PCI): 20 points with moderate ascites volume, and peritoneal cancer nodules were clearly peritoneal metastases of poorly differentiated adenocarcinoma
.
CPS score: 5 points
.
Normal mismatch repair protein (pMMR), microsatellite stable (MSS)
.
▎Treatment process: The patient was treated with intraperitoneal combined with systemic chemotherapy and PD-1 inhibitor nivolumab.
After three courses of treatment, the patient’s clinical symptoms were significantly improved, ascites began to subside, and the patient’s appetite and mental symptoms were also Significantly improved
.
After another three courses of treatment with this program, the imaging examination was performed again, and the results indicated that the patient's condition had also been greatly relieved
.
The results of laparoscopic exploration showed that the patient's ascites basically disappeared, and the peritoneal metastases disappeared completely
.
Since the patient’s peritoneal metastases were well controlled, after our evaluation, it was decided to perform surgery on the patient.
Partial gastrectomy combined with D2 lymph node dissection was performed.
The number of lymph node dissections reached 50
.
The pathological results suggest that the patient's tumor has reached a significant decline
.
At the same time, the patient basically recovered 10 days after the operation and can be discharged from the hospital
.
Summary: This case is very successful, and it is a great encouragement to our doctors in gastrointestinal surgery
.
Through this patient's treatment experience, we have also obtained very good social benefits, allowing more patients to believe that our treatment plan can provide a better prognosis for patients with advanced gastric cancer and patients with peritoneal metastasis
.
"Nivolumab combination regimen is recommended to rewrite the guidelines and approved as first-line treatment.
In recent years, the treatment of gastric cancer in China has made great progress
.
In addition to traditional radiotherapy and chemotherapy, the emergence of HER2 targets in advanced gastric cancer has made targeted therapy in Occupy a place in stomach cancer
.
However, HER2-negative patients still account for the majority.
Professor Yan Chao pointed out: "In 2021, nivolumab plus chemotherapy was approved by the National Medical Products Administration (NMPA) of China for the first-line treatment of advanced gastric cancer, which has become an important milestone.
.
released this year China Society of clinical Oncology (CSCO) Guide Conference "edition 2021 CSCO gastric cancer treatment guidelines" recommend HER2-negative population first-line use of immunotherapy, 1A type of evidence class I recommendation, immune-line treatment status improved significantly
.
"the program The approval is based on the CheckMate-649 study [1] that has attracted much attention in recent years.
This global multi-center, randomized, open-label study aims to explore a combination therapy based on nivolumab and compare it to standard chemotherapy.
The efficacy of first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
.
At the American Association for Cancer Research (AACR) annual meeting in 2021, the data of the Chinese subgroup in the CheckMate-649 study was announced.
A total of 208 Chinese patients were included in this analysis.
The results suggest that nivolumab combined with chemotherapy has a median OS of 14.
3 months, better than 10.
3 months in the standard chemotherapy group; patients with PD-L1 CPS ≥ 5 and PD-L1 CPS ≥ 1 have observed clinically significant OS benefits, and there is a trend of better benefits
.
Regardless of the entire patient population or the Chinese subgroup, regardless of the patient's PD-L1 expression level, nivolumab combined with chemotherapy has achieved a full range of breakthroughs in efficacy and produced a satisfactory report card
.
Based on the research results of CheckMate-649, immunotherapy has been advanced to the front line, and the recommendations of the "2021 CSCO Gastric Cancer Diagnosis and Treatment Guidelines" have been rewritten
.
Science is constantly advancing, and immunotherapy has achieved impressive results in the field of gastric cancer in recent years.
When everyone feels hopeless, immunotherapy has brought a ray of life
.
The CheckMate-649 research and the patients' personal experience undoubtedly bring confidence and hope to more gastric cancer patients
.
Expert Profile Professor Yan Chao, Deputy Director of Gastrointestinal Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Director of the Ward; Postdoctoral Fellow, Doctor of Medicine, Deputy Chief Physician of the Japanese Autonomous Medical University; Standing Committee Member of the Peritoneal Tumor Professional Committee of the Chinese Anti-Cancer Association; Chinese Medical Doctor Association Member of Upper Gastrointestinal Surgeons Committee of Surgeons Branch; Young Member of Gastric Cancer Professional Committee of Chinese Anti-Cancer Association; Member of Accelerated Rehabilitation Surgery Group of Gastric Cancer Professional Committee of Chinese Anti-Cancer Association; Member of Gastric Cancer Staging Subcommittee of Professional Committee of Chinese Anti-Cancer Association; China Member of the Youth Committee of the Robot Specialist Committee of the Surgeon Branch of the Physicians Association; member of the Difficult Tumor Professional Committee of the Chinese Medical Education Association; member of the Oncologist Branch of the Shanghai Medical Doctor Association; member of the Gastrointestinal Surgery Group of the General Surgery Branch of the Shanghai Medical Association; Member of the Youth Council of the Cancer Society; Member of the Endoscopic Surgery Group of the Shanghai Anti-Cancer Association Minimally Invasive Tumor Therapy Committee; Member of the Medical Education Reform Expert Steering Committee of the Shanghai Jiaotong University School of Medicine; Member of the Correspondence Editor of Chinese Journal of Gastrointestinal Surgery; Young editorial board member of Chinese Journal of Cancer
.
References: [1].
Shen L, Bai Y, Lin X, et al.
Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis[J].
Cancer Research, 2021, 81(13 Supplement): CT184 Approval number: OPDGI-DG-0029-210908-230908*This article is only It is used to provide scientific information to medical professionals, and does not represent the views of this platform.
Interviews with Chinese Gastrointestinal Cancer Medical Experts-Immunotherapy brings longer-term survival benefits for advanced gastric cancer
